@article{a4a0a7f2ba584a3598c6320776f95f90,
title = "Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis",
author = "{Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group} and Gaurav Goyal and Abeykoon, {Jithma P.} and Marie Hu and Young, {Jason R.} and Shah, {Mithun V.} and Bennani, {N. Nora} and Call, {Timothy G.} and Hook, {C. Christopher} and Animesh Pardanani and Inwards, {David J.} and Robert Vassallo and Ryu, {Jay H.} and Tobin, {W. Oliver} and Koster, {Matthew J.} and Davidge-Pitts, {Caroline J.} and Aishwarya Ravindran and Rech, {Karen L.} and Go, {Ronald S.}",
note = "Funding Information: This work was partly presented at the annual meeting of the American Society of Hematology, 2019, Orlando, FL. Funding Information: R. V. has received research funding from Pfizer, Bristol Myers Squibb and Sun Pharma. W.O.T reported receiving grants from Mallinckrodt pharmaceuticals and NIH R01 NS113803 01A1. N.N.B serves on the advisory board for Verastem. The remaining authors declare no competing financial interests. ",
year = "2021",
month = may,
day = "1",
doi = "10.1002/ajh.26119",
language = "English (US)",
volume = "96",
pages = "E146--E150",
journal = "American journal of hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "5",
}